Table 3 Reference guide for BCMA protein and mRNA expression across hematologic malignancies.
From: B-cell maturation antigen expression across hematologic cancers: a systematic literature review
Tumor type | Cell surface BCMA | sBCMA | BCMA mRNA |
|---|---|---|---|
Multiple myeloma | +10,13,14,18–23 | +14,21,24–26 | +13,19,20,27 |
T-ALL | −23 | NA | +a,27 |
B-ALL | −23 | NA | +11,27,29 |
Mature B-cell neoplasms | +10,22 −30 | NA | NA |
B-cell lymphoma | +10 | NA | NA |
DLBCL | −14,30 +10,22,23 | NA | NA |
Plasmablastic lymphoma | +10 | NA | NA |
Burkitt’s lymphoma | +10,22 | NA |  |
CLL or CLL/SLL | −14,30 +22,23,32,33 | NA | +a,27,33 |
FL | −14,30 +10,22,23 | NA | NA |
MCL | −30 +22,23 | NA | NA |
Marginal zone lymphoma | −30 +22 | NA | NA |
Waldenstrom’s macroglobulinemia | +31 | NA | NA |
HLb | −10,14 +22,34 | NA | +34 |
T-cell lymphoma | −10 | NA | NA |
Myeloid and lymphoblastic lymphoma/leukemia | −10 | NA | NA |
AMLc | +28 | NA | +28 |
